Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)

NCT07741526 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer´s Disease

Interventions

DRUG: NPI-001
DRUG: Placebo

Sponsor

Arctic Therapeutics

Collaborators

[object Object]